DB21, Galectine-1 Antagonist

DB21, Galectin-1 Antagonist is a dibenzofuran conjugated peptidomimetic that acts as an allosteric inhibitor of galectin-1 (GAL1) binding to cell surface glycans. DB21, Galectin-1 Antagonis increases inhibition of angiogenesis and tumour growth in melanoma, lung adenocarcinoma and ovarian cancer models[1].

1623027-80-4

12352209

Galectin

Immunology/Inflammation

Cancer

10 mM in DMSO

O=C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](C)C(O)=O)=O)=O)=O)=O)=O)[C@H]([C@@H](C)CC)NC(CCC1=CC=CC2=C1OC3=C2C=CC=C3CCNC([C@H](CC(C)C)NC([C@@H](NC([C@@H](CCC)NC([C@H](CCC(N)=O)NC([C@H](C(C)C)NC([C@H](CO)N)=O)=O)=O)=O)CCCCN)=O)=O)=O

C83H136N18O19

1690.08

[1]Karina V Mariño, et al. Targeting galectin-driven regulatory circuits in cancer and fibrosis. Nat Rev Drug Discov. 2023 Apr;22 (4) :295-316.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P10010/

Peptides

No Development Reported